Articles tagged with Lung Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers identified AEG-1 as a strong predictor of progression-free survival in patients with EGFR-mutant non-small cell lung cancer treated with erlotinib. Patients with low AEG-1 expression had longer progression-free survival compared to those with high expression.
Researchers discovered that zoledronic acid can prevent lung cancer metastases from recruiting new blood vessels. The drug showed a statistically significant reduction in VEGF and b-FGF levels, suggesting potential anti-angiogenic effects.
Researchers predict nearly 1.3 million cancer deaths in Europe in 2011, with a 7% drop in men's death rates and a 6% decrease in women's mortality. The number of lung cancer deaths is increasing steadily, particularly among Polish and UK women, while breast cancer mortality falls.
Cancer rates are expected to nearly double globally by 2030 due to demographic changes and adoption of unhealthy lifestyles. Preventive measures must be widely applied to mitigate the impact.
Research suggests that high levels of circulating DNA, specifically human telomerase reverse transcriptase (hTERT), can indicate a faster progression of lung cancer and lower overall survival. Patients with lower hTERT levels had improved time to progression and higher overall survival rates compared to those with higher levels.
The report finds progress in reducing cancer death rates for lung and prostate cancers among African American men. However, disparities remain, with higher mortality rates from breast, colorectal, and lung cancers in women. The study highlights the critical role of socioeconomic status in cancer disparities.
A study by Elisabetta Rapiti found that women taking tamoxifen had 87% fewer lung cancer deaths than the general population. The research supports a hormonal influence on lung cancer and estrogen's role in patients' prognosis.
Research highlights the importance of symptom management in improving quality of life for patients with stage IIIb or IV lung cancer. A study found that symptom distress was the strongest determinant of quality of life, followed by symptom severity and frequency.
A China Medical University study shows a 10.9-fold increased risk of lung cancer among people with tuberculosis compared to those without the disease. The study followed over 1 million patients and found a mortality rate of 51.1 per 10,000 person-years in the tuberculosis group, nearly six times that of non-tuberculosis patients.
A new UCSF study reveals that older men with high-risk prostate cancer are frequently under-treated, leading to higher mortality rates. The researchers argue that age should not be a barrier to more aggressive treatments that could lead to potential cures.
Patients who develop an acne-like skin rash after starting chemotherapy and cetuximab treatment have better overall survival, progression-free survival, and response rates compared to those without a rash. The study suggests that an early skin rash could be a predictor of treatment success in lung cancer patients.
Researchers at Boston University School of Medicine have received grants to develop novel tests for early detection of lung cancer in high-risk patients. The grants will focus on identifying subtle differences in cells from the nose or mouth that can detect disease.
Researchers at UT Southwestern Medical Center discovered gene expressions in lung tumors and normal tissue that predict patient survival time and guide effective treatments. The study found specific nuclear receptors associated with good prognosis and identified potential drug targets for personalized therapy.
A cluster-randomized clinical trial in Ethiopia found significantly higher nasopharyngeal pneumococcal resistance to macrolides in communities randomized to receive azithromycin compared to untreated control communities. This study highlights the impact of antibiotic selection pressure on developing antibiotic resistance.
Researchers found that adding ipilimumab to paclitaxel/carboplatin improved progression-free survival rates for stage IIIb/IV non-small cell lung cancer patients. The study suggests that ipilimumab may be a valuable addition to standard treatments, potentially leading to better patient outcomes.
Researchers identified six gene markers in early-stage non-small cell lung cancer that can predict tumor relapse and survival rates. The six-gene classifier stratifies patients into low-, intermediate- and high-risk groups with significantly different relapse rates.
Researchers compared treatment outcomes of elderly patients with early-stage lung cancer treated with either surgery or stereotactic radiation therapy. The study found that both treatments had similar long-term survival rates, but surgery had a higher risk of mortality in the first 30 days.
A study found that combining epigenetic therapy and molecular targeted therapy can improve outcomes for patients with elevated E-cadherin levels in advanced lung cancer. The treatment achieved significantly improved overall survival rates compared to erlotinib alone.
The Lancet criticizes Canada and Quebec governments for exporting asbestos, a cause of deadly mesothelioma, to developing countries. The export will continue due to a loan guarantee, sparking protests and concerns about the exploitation of vulnerable populations.
A study published in The Lancet found that low-dose aspirin reduces mortality from various cancers, including oesophagus, lung, stomach, pancreas, and possibly brain cancer, by 20-30% regardless of dose or smoking status. Benefit is seen with increasing age and may require at least five years of use for significant impact.
A study found that PET/CT scans can predict local recurrence in lung cancer patients treated with radiofrequency ablation by analyzing lesion size, tumor type, and glucose metabolic activity. This non-invasive tool may help improve diagnosis and treatment of lung cancer.
Researchers at VCU Massey Cancer Center discovered a previously unknown mechanism in NSCLC cells that contributes to their ability to maintain and grow tumors. The study found that a protein factor regulates the expression of caspase-9, a main player in apoptosis, which could provide a new target for therapies.
Researchers at SomaLogic describe a breakthrough technology that detects biomarkers for lung cancer in its early stages, revealing the presence of a panel of 12 proteins. The SOMAmer technology enables accurate detection and measurement of proteins in just a few drops of blood.
An experimental immunotherapy using a protein called MAGE-A3 is being tested to prevent lung cancer recurrence in patients who have undergone surgical removal of their tumor. The therapy has shown promising results in clinical trials, offering a potential new weapon against non-small cell lung cancer.
Researchers at MIT discovered that restoring the p53 gene function can slow down the spread of malignant lung tumors in mice, but not in benign ones. The study suggests that p53 restoration could help prevent aggressive cancers from metastasizing.
A new study finds that a less invasive method for determining lung cancer stage improves detection of metastases and reduces surgical procedures. The method, which combines endosonography and ultrasound, was more effective than traditional surgical staging in identifying patients who needed further treatment.
A new inhalable dry powder treatment for lung cancer has been shown to significantly increase survival rates, with over 80% of mice surviving for more than 90 days. The treatment method is also less invasive than traditional options, reducing the risk of side effects and improving overall patient outcomes.
A gene-based test accurately identified a subgroup of very high-risk smokers who accounted for over 50% of all lung cancer cases. The study found that targeting these individuals with low-dose CT screening could significantly improve the number of early-stage lung cancer cases found, making screening more cost-effective.
A study of adolescents found that less than 2% met annual preventive care visit recommendations, highlighting the need for better access to care. Meanwhile, a survey of family physicians revealed that many refer patients elsewhere for vaccines due to inadequate payment and lack of participation in federally-funded programs.
Researchers found distinct DNA alterations in lung tumors from smokers and never-smokers, suggesting two possible disease pathways. The study suggests that lung cancers in never-smokers require further investigation to improve detection and treatment strategies.
A gene-based test for lung cancer risk assessment motivates smokers to quit or cut down, according to a clinical study. The test, Respiragene, resulted in 32% of smokers quitting altogether and another 48% reducing their cigarette intake.
Researchers at Hebrew University of Jerusalem discovered that Vav1 plays a wider role in several types of cancer than previously thought. The discovery has implications for targeting this gene in cancer research and identifying potential therapeutic targets.
A national study conducted by the National Cancer Institute found that CT scanning can reduce lung cancer deaths by 20% in former and current heavy smokers. The study, which involved over 53,000 participants, compared low-dose helical CT with standard chest X-ray screening.
Researchers found that screening for lung cancer using helical CT scanning reduced lung cancer deaths by 20 percent compared to chest X-rays. The study also showed overall deaths due to any factor were 7 percent lower in those screened with low-dose helical CT.
A new study published in the New England Journal of Medicine found that crizotinib caused tumors to stop growing, shrink or disappear in 57-33 percent of patients with a specific genetic mutation. This represents a significant improvement over the current standard treatment, which has a response rate of around 15 percent.
Researchers found lung adenocarcinomas in young patients with pediatric cancers, displaying similar gene mutations as adult cases. The tumors may occur prior to chemotherapy treatment and are not always secondary malignancies.
A study published in the New England Journal of Medicine found that over half of patients with a specific type of lung cancer responded well to a new targeted treatment called crizotinib. The medication targets the gene driving the cancer and has been shown to improve patient outcomes, including reduced tumor growth and improved qualit...
Researchers found that maternal KIRs interacting with fetal HLA-C molecules determine trophoblast invasion, affecting recurrent miscarriage and preeclampsia. Meanwhile, a new approach to treating thrombocytopenia involves infusing mature megakaryocytes into mice to generate functional platelets.
Researchers at IRIC discovered a protein complex, EJC, that controls the production of MAPK protein, which acts directly on cells. Targeting this complex could prevent abnormal signal transmission that triggers several cancers.
A biomarker called TCF21 has shown promise in developing a potential screening test for early-stage lung cancer. The biomarker's abnormal expression was found in over 80% of non-small-cell lung cancers, suggesting its potential as a diagnostic tool.
A Phase IIb/III trial shows afatinib benefits patients with lung adenocarcinoma whose cancer progressed after chemotherapy and erlotinib or gefitinib. Patients receiving afatinib experienced delayed disease progression and greater tumor shrinkage, but no significant difference in overall survival.
A Phase II study of the new-generation lung cancer drug PF-299 has shown impressive results in preventing disease progression when administered as a first-line treatment in patients with advanced disease. The study found that 85% of patients with EGFR mutations remained progression-free for at least nine months.
In a phase II study, patients with locally advanced and metastatic NSCLC experienced significant increases in survival time when treated with TTF therapy in combination with chemotherapy. The therapy has also been shown to have clinical efficacy in human trials for other solid tumors, including recurrent glioblastoma.
Erlotinib has been shown to improve progression-free survival in patients with advanced lung cancer carrying EGFR activating mutations. The OPTIMAL trial found that erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination. Safety analyses also showed lower rates of adverse events with erlotinib.
A new drug targeting the MET receptor added benefit to erlotinib in patients with advanced lung cancer who express MET, improving overall survival and progression-free survival
A new clinical study reveals a technique called partial wave spectroscopic microscopy can differentiate individuals with lung cancer from those without, even in lifetime smokers or COPD patients. The findings suggest that this minimally invasive test could lead to personalized screening for lung cancer, the leading cause of cancer deat...
Researchers developed a method to detect early signs of lung cancer by examining cheek cells using biophotonics technology. The test, called partial wave spectroscopic (PWS) microscopy, shows promise in prescreening patients at high risk for the disease.
A retrospective study found that African-American patients had a lower median overall survival rate due to factors such as age, stage, and type of treatment, rather than their race. Patients of other races, including Asian and Hispanic patients, had a better disease prognosis.
A new study published in the Journal of Thoracic Oncology found that approximately half of advanced non-small cell lung cancer patients received chemotherapy treatment, exceeding previous estimates. The retrospective analysis showed age and insurance type were associated with chemotherapy administration.
The TRUST study found that erlotinib significantly increased survival for patients with previously treated advanced NSCLC. Certain patient groups, such as adenocarcinoma, women, and Asian ethnicity, showed greater tumor responses to EGFR TK inhibitors.
A study by the University of Melbourne found that close relatives of women diagnosed with breast cancer before age 35 have a higher risk of developing other cancers. These include prostate, lung, brain, and urinary tract cancers, with increased risks ranging from 2 to 8 times higher than expected.
Researchers at Boston University School of Medicine have discovered a key protein factor, Ets1, involved in the progression of lung cancer. The study aims to identify new therapeutic targets to block tumor growth and metastasis, offering hope for improved patient outcomes.
A 40-year-long tobacco control program in California has led to significant reductions in smoking rates, resulting in lower lung cancer mortality. The study credits the state's aggressive tax on cigarettes and comprehensive tobacco control efforts.
Researchers found that African-American patients with non-small cell lung cancer have similar rates of EGFR mutations, making targeted therapies like erlotinib a viable option. This discovery challenges previous assumptions about racial disparities in lung cancer treatment.
The study found that radiation exposure increases the risk of both first and second cancers to a similar degree, with higher risks for radiation-sensitive cancers like lung, colon, breast, thyroid, and bladder cancers. Cancer survivors with a history of radiation exposure should continue to be closely monitored for second cancers.
Researchers at UT Southwestern Medical Center have found that overexpressing microRNA-21 promotes the formation, growth and survival of new tumors in mice with non-small-cell lung cancer. The study suggests that inhibiting miR-21 could be a therapeutic approach to treating the disease.
A study by Heike Allgayer's team found that micro-RNA miR-200c inhibits the motility and invasive capacity of non-small cell lung cancer cells. Higher miR-200c levels were associated with increased tissue-anchoring molecules and lower metastasis rates.
A genetic signature has been identified that can help doctors determine which patients with early-stage non-small cell lung cancer are at high risk for developing disease recurrence and may benefit from chemotherapy after surgery. The study found that the 15-gene signature predicted aggressive disease in 62 patients, and those with agg...
A study found that tumor budding is a distinct morphologic feature with biologic and prognostic significance in lung adenocarcinoma, significantly linked to aggressive disease characteristics. The presence of tumor budding was also associated with lower five-year survival rates.
A study published in Journal of Thoracic Oncology found that using the histoculture drug response assay to guide chemotherapy improves lung cancer survival and prognosis for patients who have undergone surgery. The use of adjuvant chemotherapy based on assay results showed a higher five-year survival rate compared to traditional treatm...